CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 26, 2024—Proscia has partnered with Nucleai, a spatial artificial intelligence biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes. The companies will integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and make them available as part of Proscia’s precision medicine AI portfolio.
Nucleai’s predictive biomarkers create an AI-guided spatial map of a patient biopsy that aims to help laboratories target recruitment and optimize execution for the clinical trials they support. The spatial mapping also enables Nucleai’s applications to serve as companion diagnostics that match patients to the most effective treatment.
“Together, Proscia and Nucleai will enable more pathologists and clinicians to convert the complex data from patient biopsies into precise, actionable insights that can drive better clinical trial and diagnostic decisions,” said Nucleai CEO Avi Veidman. “Our partnership holds tremendous promise for advancing next-generation treatment modalities like ADCs [antibody-drug conjugates], multispecifics, immunotherapy, and combination therapies. With the recent deployment of our technology to aid patient enrollment for an active trial and the growing need for AI-powered biomarkers across trials and diagnostics, this partnership represents a significant step forward in deploying our solutions, at scale.”